# Bioresorbable Sirolimus-Eluting Scaffold Treatment for Below the Knee Disease

Study · id `cardio:ct-nct06071429` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06071429](<https://clinicaltrials.gov/study/NCT06071429>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06071429

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

## Technical summary

Registry record NCT06071429. Randomized; single masking; primary purpose treatment. Start 2025-04-11 (actual); primary completion 2028-03-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT06071429, source copy `cardio:ctgov-nct06071429-2026-02-06`, retrieved 2026-10-31)
- Started: 2025-04-11 (actual) (ClinicalTrials.gov record NCT06071429, source copy `cardio:ctgov-nct06071429-2026-02-06`, retrieved 2026-10-31)
- Primary completion: 2028-03-01 (anticipated) (ClinicalTrials.gov record NCT06071429, source copy `cardio:ctgov-nct06071429-2026-02-06`, retrieved 2026-10-31)
- Completion: 2032-03-01 (anticipated) (ClinicalTrials.gov record NCT06071429, source copy `cardio:ctgov-nct06071429-2026-02-06`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT06071429, source copy `cardio:ctgov-nct06071429-2026-02-06`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06071429-2026-02-06`, retrieved 2026-10-31)

## The registry's words

- Brief title: Bioresorbable Sirolimus-Eluting Scaffold Treatment for Below the Knee Disease
- Acronym: ELITE-BTK
- Condition: Chronic Limb-Threatening Ischemia
- Intervention (Device): MAGNITUDE Sirolimus-eluting Bioresorbable Scaffold
- Intervention (Device): Percutaneous Transluminal Angioplasty (PTA)
- Lead sponsor: R3 Vascular Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)

## Provenance

Content hash: 7d434534aced34d39f8b12bac601da1b21a7216e85254d1570d56b1cf6797405
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
